-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shanghai Pharmaceuticals announced that it has reached an exclusive license agreement with HUYABIO, authorizing it to obtain the rights to manufacture, develop and commercialize SPH6162 outside of China
.
This is the first overseas licensing project of Shanghai Pharmaceuticals, and it is also a milestone event that marks the significant progress of the company's R&D and innovation capabilities
.
The disclosed information shows that SPH6162 is a small molecule chemical drug independently developed by Shanghai Pharmaceuticals.
It is a kinase inhibitor that can kill tumor cells by inhibiting tumor cell damage and repair
.
In this license-out cooperation, HUYABIO intends to pay a milestone payment of no more than US$292.
5 million plus a 3-6% sales commission to obtain the exclusive product development, production and sales of Shanghai Pharmaceutical’s new anti-tumor drug SPH6162 outside of China.
The right to authorize and sublicense
.
In addition, the two parties also expect to establish a joint development committee to coordinate the development and commercialization of global products
.
In recent years, China’s biosimilar drug market is actually in a period of rapid development, especially after the National Medical Products Administration has accelerated the drug R&D approval process, the number of domestic companies with biosimilar drugs has almost reached 180, with nearly 400 drugs.
.
It is worth mentioning that, as the results of drug research and development continue to emerge, the overseas sales of Chinese pharmaceutical companies' products have also begun to increase, which is no longer a new concept
.
Specifically, as early as ten years ago, domestic pharmaceutical companies pioneering international market expansion, including Huahai Pharmaceutical, Hengrui Pharmaceutical, Hisun Pharmaceutical, Shandong Luye, etc.
, have achieved the success of generic drugs in the United States through the ANDA approach.
It's just that the promotion of new drugs in overseas markets was still relatively weak for most Chinese pharmaceutical companies at the time
.
However, with the acceleration of domestic biosimilar drug research and development competition, Chinese pharmaceutical companies have more diversified rights and interests overseas, including the commercialization of late-stage or marketed products, the development and commercialization of technology platforms and early-stage clinical products
.
It is reported that in 2020, Biotech, Henlius and Cinda Biotech will all authorize the commercialization rights of biosimilar drugs overseas, and the domestic and overseas markets will be robbed together.
.
In addition, there are data showing that in 2020, the number of Chinese medicines going overseas has reached 23, and as of August 2021, there have been 13 overseas authorized projects
.
Among them, it is worth mentioning that Eli Lilly, a multinational pharmaceutical company that digs more treasures in China last year, has been authorized for 3 new drugs, in addition to continuing to expand its global cooperation based on Sintilizumab with Cinda , Also obtained the right to develop the new crown neutralizing antibody from Junshi, and also obtained the development of FCN-338, a selective inhibitor of B-cell lymphoma-2 (BCL-2) from Fosun Pharma, outside of Greater China Right
.
In general, behind the license out of local pharmaceutical companies, it means that China’s new drug R&D strength is gradually being recognized by overseas markets, and it no longer only relies on foreign companies to "import" innovative drugs; it also means that Chinese local innovative companies are exploring Subdivide the cooperation and development in technical fields, and continuously improve the efficiency of new drug development
.
.
This is the first overseas licensing project of Shanghai Pharmaceuticals, and it is also a milestone event that marks the significant progress of the company's R&D and innovation capabilities
.
The disclosed information shows that SPH6162 is a small molecule chemical drug independently developed by Shanghai Pharmaceuticals.
It is a kinase inhibitor that can kill tumor cells by inhibiting tumor cell damage and repair
.
In this license-out cooperation, HUYABIO intends to pay a milestone payment of no more than US$292.
5 million plus a 3-6% sales commission to obtain the exclusive product development, production and sales of Shanghai Pharmaceutical’s new anti-tumor drug SPH6162 outside of China.
The right to authorize and sublicense
.
In addition, the two parties also expect to establish a joint development committee to coordinate the development and commercialization of global products
.
In recent years, China’s biosimilar drug market is actually in a period of rapid development, especially after the National Medical Products Administration has accelerated the drug R&D approval process, the number of domestic companies with biosimilar drugs has almost reached 180, with nearly 400 drugs.
.
It is worth mentioning that, as the results of drug research and development continue to emerge, the overseas sales of Chinese pharmaceutical companies' products have also begun to increase, which is no longer a new concept
.
Specifically, as early as ten years ago, domestic pharmaceutical companies pioneering international market expansion, including Huahai Pharmaceutical, Hengrui Pharmaceutical, Hisun Pharmaceutical, Shandong Luye, etc.
, have achieved the success of generic drugs in the United States through the ANDA approach.
It's just that the promotion of new drugs in overseas markets was still relatively weak for most Chinese pharmaceutical companies at the time
.
However, with the acceleration of domestic biosimilar drug research and development competition, Chinese pharmaceutical companies have more diversified rights and interests overseas, including the commercialization of late-stage or marketed products, the development and commercialization of technology platforms and early-stage clinical products
.
It is reported that in 2020, Biotech, Henlius and Cinda Biotech will all authorize the commercialization rights of biosimilar drugs overseas, and the domestic and overseas markets will be robbed together.
.
In addition, there are data showing that in 2020, the number of Chinese medicines going overseas has reached 23, and as of August 2021, there have been 13 overseas authorized projects
.
Among them, it is worth mentioning that Eli Lilly, a multinational pharmaceutical company that digs more treasures in China last year, has been authorized for 3 new drugs, in addition to continuing to expand its global cooperation based on Sintilizumab with Cinda , Also obtained the right to develop the new crown neutralizing antibody from Junshi, and also obtained the development of FCN-338, a selective inhibitor of B-cell lymphoma-2 (BCL-2) from Fosun Pharma, outside of Greater China Right
.
In general, behind the license out of local pharmaceutical companies, it means that China’s new drug R&D strength is gradually being recognized by overseas markets, and it no longer only relies on foreign companies to "import" innovative drugs; it also means that Chinese local innovative companies are exploring Subdivide the cooperation and development in technical fields, and continuously improve the efficiency of new drug development
.
